Leading global genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter, which delivers expert genomics sequencing solutions to healthcare businesses, as well as academic and government institutions worldwide (GS).
“The genomic services business of Beckman Coulter is an ideal fit with GENEWIZ’s global strategy and expansion plans,” said Dr. Steve Sun, GENEWIZ Chairman and CEO. “Our two companies share a common mission and vision, to offer scientists around the world consistently-reliable genomics service solutions that will advance innovations and scientific discoveries.”
The synergies of this acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25+ years of genomics expertise and capabilities. GS’s comprehensive Sanger Sequencing, Next Generation Sequencing, Bioinformatics, and CLIA/Clinical services will complement GENEWIZ’s existing genomics services. With an international presence in the U.S. and a Pan-European presence centered in the UK, GS presents an immediate opportunity to strengthen GENEWIZ’s global access and value to customers through a stronger network of global labs and office locations in the U.S., UK, China, and Japan.
“GS’s proven leadership and experienced team of industry experts have built an efficient workflow that allows for the delivery of quality and timely results to its customers,” continued Dr. Sun. “The integration of these two businesses will allow for an increased level of service and value to customers worldwide. We look forward to working with the talented GS team to best serve our customers, and be an instrumental part of the future growth of GENEWIZ.”
GS and GENEWIZ will collaboratively align to ensure there is a seamless transition for both organizations and its customer base. The agreement has been approved by the boards of directors of both companies and closed effective immediately.
Source: GENEWIZ
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.